The recent incorporation of AI into SNAC’s research pipelines has rapidly accelerate the development of neuroimaging ‘smarts’ for both clinical trials and the diagnostic imaging industry.
Awarded an A$2.36 million industry grant by the Australian government in 2018, SNAC is working with I-MED Radiology, one of the largest imaging providers in the world, and the University of Sydney’s Brain and Mind Centre to transform the delivery of neuroradiology with AI. SNAC’s expanding library of AI neuroimaging algorithms is accelerating the development and translation of biomarkers in neurological disease. Direct integration of these algorithms with clinical systems (PACS and RIS) is seamlessly enhancing productivity and accuracy in clinical radiology workflows.
Sydney Neuroimaging Analysis Center (SNAC) has been an extraordinary partner in our clinical plans for our lead asset. When we considered Australia for our clinical trial work in neurodegenerative disease, it was quickly apparent that SNAC was the right partner. We’ve been incredibly grateful for the support we’ve received from every team member at SNAC; the SNAC team members consistently provide a level of professionalism and solid collaboration in the rigorous clinical framework required for pharmaceutical clinical drug development. Clene looks forward to further partnership with SNAC.
— Rob Etherington , President & CEO , Clene Nanomedicine